Opaxio & Pixantrone Drugs for New Cancer Treatment/Clinical Trails

Here are few new drugs in the pipeline and some for Ovarian Cancer, Breast Cancer, Non-Hodgkins Lymphoma & more. A MUST READ!

Opaxio and Pixantrone are being used as a maintenance drug for Ovarian Cancer and as a sensitize for Esophageal Cancer and for aggressive Hodgkin Lymphoma. 
According to Cell Therapeutics' website they "Our cancer drug development pipeline includes a biologically enhanced taxane, a new compound designed to treat cancers normally treated with anthracyclines, and a DNA minor groove binding agent—each of which has the potential to treat a variety of cancer types."

They also have a variety of clinical trials.

Ovarian Cancer Trials (Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer)

Glioblastoma Multiforme Anaplastic Glioma Trials 

Breast Cancer-HER2 Negative Trial 

The PIX-R TRIAL is a randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with Diffuse Large B-Cell Lymphoma (DLBCL) who have relapsed after therapy with CHOP-R or an equivalent regimen and are ineligible for stem cell transplant